| Website | cylenepharma.com |
| Category | BioTech |
| Phone | 858-875-5100 |
| Employees |
| TOTAL | $56M |
| VENTURE FUNDING TOTAL | $56M |
| Series C, 1/07 HBM BioVentures Lilly Ventures | $44M |
| Series D, 9/10 HBM BioVentures Novartis Bioventures Bioventures Investors Lilly Ventures Mitsui & Co Morningside Venture Investments | $12M |
Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs that target nucleolus and kill cancer cells. It offers nucleolus targeting agents, which are small-molecule targeted cancer therapeutic agents for carcinoid/neuroendocrine tumors and pediatric brain tumors; and serine/threonine protein kinase inhibitors. The company also provides pre-clinical stage oral drug candidates. Cylene Pharmaceuticals, Inc. was founded in 1997 as Cyternex, Inc. and changed its name to Cylene Pharmaceuticals, Inc. in October 2003. The company is based in San Diego, California.
